Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Dermatitis symbols : AMGN save search
Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
Published: 2021-10-02 (Crawled : 12:20) - prnewswire.com
AMGN | News | $273.01 -0.19% -0.17% 400
|
Health Technology
| Email alert
Add to watchlist
BGNE | $144.12 3.69% 3.48% 150
|
Health Technology
| Email alert
Add to watchlist
phase 2 positive dermatitis atopic dermatitis
Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
AMGN | News | $273.01 -0.19% -0.17% 400
|
Health Technology
|
| O: 1.55%
H: 0.92%
C: -0.16%
phase 2 europe dermatitis atopic dermatitis
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Published: 2021-06-01 (Crawled : 09:00) - biospace.com/
BGNE | $144.12 3.69% 3.48% 150
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
AMGN | News | $273.01 -0.19% -0.17% 400
|
Health Technology
|
| O: 1.79%
H: 0.03%
C: -3.56%
treatment potential dermatitis phase 3 atopic dermatitis
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.